Table 2.
A comparison of serum concentrations of GFAP (ng/mL) between RRMS patients and healthy individuals.
| RRMS patients n=58 | (P-value) | |||||
|---|---|---|---|---|---|---|
| Assay | Active n=22 | Inactive n=36 | Healthy subjects n=50 | ANOVA test | LSD test | |
| Serum GFAP | (6.47±3.39) | (5.33±2.82) | (1.89±1.21) | P<0.001 | p1 =0.074 NS | |
| ng/mL | 1.022 | 0.665 | 0.24 | Highly significant | p2 <0.001 HS | |
| (Mean±SD) SEM | p3 <0.001 HS | |||||
| Serum GFAP | Hyper (>cut-off) | (20) 90.9% | (32) 88.9% | (12) 24% | p<0.001 | p1 =0.806 NS |
| ng/mL (cut-off | Normal (<cut-off) | (2) 9.1% | (4) 11.1% | (38) 76% | Highly significant | p2 <0.001 HS |
| p3 <0.001 HS | ||||||
Note: p1=Active vs. inactive, p2=Active vs. healthy donors, p3=Inactive vs. healthy donors, NS =Non-significant difference at p values above 0.05, S=Significant difference at p values below 0.05, HS=Highly significant difference at p values below 0.01.